Misplaced Pages

Amlodipine/celecoxib

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Cholesterol and blood pressure medication

Pharmaceutical compound
Amlodipine/celecoxib
Combination of
AmlodipineCalcium channel blocker
CelecoxibNonsteroidal anti-inflammatory drug (NSAID)
Clinical data
Trade namesConsensi
AHFS/Drugs.comMonograph
License data
Routes of
administration
By mouth
ATC code
Legal status
Legal status
Identifiers
KEGG

Amlodipine/celecoxib, sold under the brand name Consensi, is a fixed-dose combination medication used to treat both hypertension and osteoarthritis at the same time in adults. It contains amlodipine, as the besilate, and celecoxib. It is taken by mouth.

The most common side effects include edema, abdominal pain, diarrhea, dyspepsia, flatulence, peripheral edema, accidental injury, dizziness, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, and rash.

It was approved for medical use in the United States in May 2018.

Medical uses

Amlodipine/celecoxib is indicated for use in adults for whom treatment with amlodipine for hypertension and celecoxib for osteoarthritis are appropriate.

History

Amlodipine/celecoxib was approved for use in the United States in May 2018.

References

  1. ^ "Consensi- amlodipine besylate and celecoxib tablet". DailyMed. 17 December 2019. Retrieved 14 May 2020.
  2. Smith SM, Cooper-DeHoff RM (February 2019). "Fixed-Dose Combination Amlodipine/Celecoxib (Consensi) for Hypertension and Osteoarthritis". The American Journal of Medicine. 132 (2): 172–174. doi:10.1016/j.amjmed.2018.08.027. PMID 30240679. S2CID 52312672.
  3. ^ "Drug Approval Package: Consensi (amlodipine and celecoxib)". U.S. Food and Drug Administration (FDA). 29 November 2018. Retrieved 14 May 2020.
Ion channel modulators
Calcium
VDCCsTooltip Voltage-dependent calcium channels
Blockers
Activators
Potassium
VGKCsTooltip Voltage-gated potassium channels
Blockers
Activators
IRKsTooltip Inwardly rectifying potassium channel
Blockers
Activators
KCaTooltip Calcium-activated potassium channel
Blockers
Activators
K2PsTooltip Tandem pore domain potassium channel
Blockers
Activators
Sodium
VGSCsTooltip Voltage-gated sodium channels
Blockers
Activators
ENaCTooltip Epithelial sodium channel
Blockers
Activators
ASICsTooltip Acid-sensing ion channel
Blockers
Chloride
CaCCsTooltip Calcium-activated chloride channel
Blockers
Activators
CFTRTooltip Cystic fibrosis transmembrane conductance regulator
Blockers
Activators
Unsorted
Blockers
Others
TRPsTooltip Transient receptor potential channels
LGICsTooltip Ligand gated ion channels
See also: Receptor/signaling modulatorsTransient receptor potential channel modulators
Portal:
Stub icon

This drug article relating to the cardiovascular system is a stub. You can help Misplaced Pages by expanding it.

Categories: